Amnesty says COVID jab producers are causing human rights crisisAmnesty International has slammed the six pharma companies behind the bulk of COVID-19 vaccine supplies for not agreeing Share XAmnesty says COVID jab producers are causing human rights crisishttps://pharmaphorum.com/news/amnesty-says-covid-jab-producers-are-causing-human-rights-crisis/
Preparing for a post-pandemic worldJanssen’s Mark Hicken, VP of strategy, EMEA, looks at what COVID-19 has taught us and how we can Share XPreparing for a post-pandemic worldhttps://pharmaphorum.com/sales-marketing/janssen-mark-hicken-pharma-post-pandemic/
NICE changes its mind on J&J’s Erleada in prostate cancerNICE has reversed its position on Johnson & Johnson’s oral prostate cancer therapy Erleada in patients with hormone-relapsed Share XNICE changes its mind on J&J’s Erleada in prostate cancerhttps://pharmaphorum.com/news/nice-changes-its-mind-on-jjs-erleada-in-prostate-cancer/
Pfizer raises pressure on GSK, J&J with late-stage RSV vaccine trialPfizer has vaulted ahead with its respiratory syncytial virus (RSV) vaccine, closing the gap with GlaxoSmithKline and Johnson Share XPfizer raises pressure on GSK, J&J with late-stage RSV vaccine trialhttps://pharmaphorum.com/news/pfizer-raises-pressure-on-gsk-jj-with-late-stage-rsv-vaccine-trial/
FDA clears J&J’s twice-yearly Invega for schizophreniaOne of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson’s pharma unit Share XFDA clears J&J’s twice-yearly Invega for schizophreniahttps://pharmaphorum.com/news/fda-clears-jjs-twice-yearly-invega-for-schizophrenia/
NICE rejects J&J’s Darzalex regimen for multiple myelomaNew guidance from NICE has rejected a combination regimen based on Johnson & Johnson’s Darzalex for a group Share XNICE rejects J&J’s Darzalex regimen for multiple myelomahttps://pharmaphorum.com/news/nice-rejects-jj-darzalex-regimen-for-multiple-myeloma/
J&J lung cancer initiative will use Optellum’s ‘digital biomarker’ techThree years ago, Johnson & Johnson set up a wide-ranging initiative with Boston University to try to improve Share XJ&J lung cancer initiative will use Optellum’s ‘digital biomarker’ techhttps://pharmaphorum.com/news/jj-teams-up-with-optellum-on-digital-biomarker-tech-lung-cancer/
Alex Gorsky will pass leadership of J&J to Joaquin Duato in JanuaryJohnson & Johnson has appointed Joaquin Duato as chief executive officer to replace long-serving Alex Gorsky, who has Share XAlex Gorsky will pass leadership of J&J to Joaquin Duato in Januaryhttps://pharmaphorum.com/news/alex-gorsky-will-pass-leadership-of-jj-to-joaquin-duato-in-january/
Is J&J nearing the end of its opioid liability hangover?Johnson & Johnson and the ‘big three’ US pharma wholesalers are on the brink of a $26 billion Share XIs J&J nearing the end of its opioid liability hangover?https://pharmaphorum.com/news/is-jj-nearing-the-end-of-its-opioid-liability-hangover/
